Overcoming barriers to new treatment options for hepatitis c

Nurse Practitioner

Volumn 35, Issue 7, 2010, Pages 20-29

  Brennan, Christine S ^a  

^a LSUHSC School of Public Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

ALTERNATIVE MEDICINE; ARTICLE; COST OF ILLNESS; HEALTH BEHAVIOR; HEALTH CARE DELIVERY; HEPATITIS C; HUMAN; MALE; MIDDLE AGED; NURSE PRACTITIONER; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; SELF CARE; UNITED STATES;

ANTIVIRAL AGENTS; COMPLEMENTARY THERAPIES; COST OF ILLNESS; HEALTH BEHAVIOR; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; NURSE PRACTITIONERS; NURSING ASSESSMENT; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RIBAVIRIN; RISK ASSESSMENT; SELF CARE; UNITED STATES;

EID: 77957005806     PISSN: 03611817     EISSN: 15388662     Source Type: Journal    
DOI: 10.1097/01.NPR.0000383656.22286.10     Document Type: Article

References (18)

1. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5 suppl 1):S30-S34.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
3. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12(2):96-102.
4. Lo Re V 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J. 2005;81(956):376-382.
5. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36 (5 suppl 1):S21-S29.
6. Department of Veterans Affairs Hepatitis C Resource Center, Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the department of veterans affairs hepatitis C resource center program and the national hepatitis C program office. Am J Gastroenterol. 2006;101(10):2360-2378.
7. Dieperink E, Willenbring M, Ho SB. Neuropsychiatrics symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry.2000; 157(6):867-876.
8. Silberbogen AK, Ulloa EW, Janke EA, Mori DL. Psychosocial issues and mental health treatment recommendations for patients with hepatitis C. Psychosomatics. 2009;50(2):114-122.
9. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 2009;16(2):75-90.
10. Gordon SC, Sherman KE. Treatment of HBV/HCV coinfection: releasing the enemy within. Gastroenterology. 2009;136(2):393-396.
11. Mehta G, Rothstein KD. Health maintenance issues in cirrhosis. Med Clin North Am. 2009;93(4):901-915.
12. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(5 suppl 1):S237-S244.
13. Benson L, Birkel A, Caldwell L, Stafford-Fox V, Casarico B. Advances in the treatment of hepatitis C: combination antiviral therapy with interferon alfa-2b and ribavirin. J Am Acad Nurse Pract. 2000;12(9):364-373.
14. Burra P. Hepatitis C. Semin Liver Dis. 2009;29(1):53-65.
15. Bruchfeld A, Lindahl K, Reichard O, Carlsson T, Schvarcz R. Pegylated interferon and ribavirin in haemodialysis patients. Nephrol Dial Transplant. 2006;21(5):1444-1446.
16. Webster DP, Klenerman P, Collier J, Jeffery KJ. Development of novel treatments for hepatitis C. Lancet Infect Dis. 2009;9(2):108-117.
17. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology. 2001;34(3):595-603.
18. Mehta SH, Thomas DL, Sulkowski MS, Safaein M, Vlahov D, Strathdee SS. A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS. 2005;19(suppl 3):S179-S189.